TheraRadar
← Back
Data updated: May 24, 2026

LEO PHARMA AS

Big Pharma
ImmunologyDermatologyOncology Execution: Excellent

LEO PHARMA AS is a major pharmaceutical company focused on Immunology, Dermatology, Oncology. Key products include ADBRY.

1993
Since
9
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
6 Small Molecules 1 Biologics
Novel Drugs (2021-2025):
2 Novel Approvals 1 First-in-Class

LEO PHARMA AS at a Glance

  • Strong track record with 90% execution quality across 172 trials
  • Fast trial execution (9 months median completion)

Key Drugs

Top revenue-generating and strategically important drugs approved in the last 15 years. These represent the company's core commercial portfolio.

ANZUPGO
Dermatology

Chronic Hand Eczema

JAK1 Approved 2025
ADBRY
Immunology

Atopic Dermatitis

IL-13 Approved 2021
ENSTILAR
Immunology

Plaque Psoriasis

Glucocorticoid receptor Approved 2015

Recent FDA Approvals

New drug approvals (NDA/BLA) in the last 2 years. Shows novel drugs only, excluding generics and label supplements.

ANZUPGO NDA
2025-07-23
delgocitinib
Chronic Hand Eczema

Therapeutic Areas

Disease areas where this company has approved drugs and active pipeline. Weighted by commercial stage: approved drugs count most, followed by late-stage trials.

Immunology 50%
2 drugs Phase 3: 15 Phase 2: 20 Phase 1: 24
Dermatology 48%
2 drugs Phase 3: 17 Phase 2: 16 Phase 1: 19
Oncology 1%
0 drugs Phase 3: 1
Metabolic 0%
0 drugs Phase 1: 1

Pipeline Snapshot

Active clinical trials across all therapeutic areas. Data from ClinicalTrials.gov.

33
Phase 3
36
Phase 2
44
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • ANZUPGO leads revenue
  • • 3 key drugs tracked
View revenue breakdown →

Trial Catalysts

  • • Immunology pipeline focus
  • • Phase 3 readout tracking
View full pipeline →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis
View patent timeline →

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Compare with competitor →

Execution Intelligence

  • • Phase 3: 39/44 completed
  • • Speed: 9 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges